Intellia, Gene Editing
Digest more
New technology enables the insertion of a large segment of DNA into a genome, potentially expanding gene therapy treatment ...
Frontier AI firm Profluent has entered a multi-program strategic research collaboration with Eli Lilly and Co. LLY to develop and commercialize custom site-specific recombinases to treat genetic ...
Profluent and Lilly teamed up on AI‑designed enzymes in a deal worth up to $2.25B. Big tech, bigger gene edits.
Learn more Eli Lilly is locking down on its rapid expansion strategy with a second deal this week – joining forces with artificial intelligence (AI) biotech, Profluent, to develop recombinases for ...
Eli Lilly and Co. is taking another step to bolster its genetic medicine portfolio, this time through a $2.25 billion deal ...
That is because scientists keen to achieve more precise control over an organism’s genetics are experimenting with a ...
A major collaboration involving nine labs, led by scientists at Gladstone Institutes, has transferred a particularly useful ...
The CRISPR gene editing technique has had a dramatic influence on biomedical research, and has even been applied to a few humans to treat disease. Since its invention, scientists have improved, ...
Researchers have introduced 'prime assembly,' a genome editing approach that allows insertion of large DNA segments, enabling entire gene replacements. The method avoids harmful double-strand ...
The ability to precisely edit the genomes of bacteria has long been a goal of microbiologists. Such technology would enable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results